Targets › HBB
5 programs from 5 companies in 5 trials: 4 Phase 1, 1 Phase 3; Hematology; next expected readout Dec 2026.
Involved in oxygen transport from the lung to the various peripheral tissues..; FUNCTION: LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.; FUNCTION: [Spinorphin]: Functions as an endogenous inhibitor of enkephalin-degrading enzymes such as DPP3, and as a selective antagonist of the P2RX3 receptor which is involved in pain signaling, these properties implicate it as a…. (UniProt, P68871)
Open in Phaseline: the race on HBB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Genetix Biotherapeutics | Lovotibeglogene Autotemcel (bb1111) Hemoglobin beta chain exogenous gene | HBB | Phase 3 | Sickle Cell Disease | May 2027 |
| Shenzhen Hemogen | β-globin restored autologous hematopoietic stem cells (HGI-001) Lentiviral-transduced CD34+ HSCs with LentiHBBT87Q delivering functional β-globin gene | HBB | Phase 1 | Β-thalassemia | Dec 2026 |
| San Rocco Therapeutics | Autologous CD34+ cells transduced with TNS9.3.55 Lentiviral vector encoding normal human β-globin gene for ex vivo transduction of autologo | HBB | Phase 1 | Confirmed Diagnosis of ß-thalassemia Major | Jul 2027 |
| Children's Hospital of Philadelphia | ALS20 lentiviral vector delivering beta globin gene | HBB | Phase 1 | Beta-Thalassemia | Dec 2027 |
| Mark Walters, MD | CRISPR_SCD001 CRISPR/Cas9-edited hematopoietic stem progenitor cells (CD34+) with sickle allele modifica | HBB | Phase 1 | Sickle Cell Disease | Mar 2030 |
Sickle Cell Disease (2) Beta-Thalassemia (1) Β-thalassemia (1) Confirmed Diagnosis of ß-thalassemia Major (1)
other (3), protein or peptide (1)
Children's Hospital of Philadelphia (1) Mark Walters, MD (1) Shenzhen Hemogen (1) Genetix Biotherapeutics (1) San Rocco Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.